Free Trial
→ Here’s how you could profit from Elon’s NVIDIA partnership (From Behind the Markets) (Ad)

Annexon Q4 2022 Earnings Report

Annexon logo
$2.81 -0.02 (-0.71%)
As of 04:00 PM Eastern
Earnings HistoryForecast

Annexon EPS Results

Actual EPS
-$0.48
Consensus EPS
-$0.53
Beat/Miss
Beat by +$0.05
One Year Ago EPS
N/A

Annexon Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Annexon Announcement Details

Quarter
Q4 2022
Date
3/6/2023
Time
Q4 2022 Earnings Release

Conference Call Resources

Annexon Earnings Headlines

Annexon reports inducement grants under Nasdaq listing rule
February 19 at 4:43 AM | markets.businessinsider.com
Analysts Set Annexon, Inc. (NASDAQ:ANNX) Target Price at $15.80
February 19 at 1:33 AM | americanbankingnews.com
9/9 on TSLA from June to January
Please take a look at THIS case study on Target (TGT) You’ll see exactly how the tool works to trade long and short, even when the markets seem to be predicting the exact opposite. Now, this tool has been so accurate over recent months that I’m planning to send you 14 more real-world examples of winning trades that anyone using this tool could have captured. And it’s all building to Monday, February 24 @ 1pm ET when I’ll bring the tool to the public for the first time and show you how you can put it on your own charts!
February 21, 2025 | Wealthpin Pro (Ad)
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
February 18 at 8:00 AM | globenewswire.com
Annexon Announces Presentations Highlighting ANX007 Functional and Structural Differentiation in Geographic Atrophy at the Macula Society 48th Annual Meeting
February 13, 2025 | globenewswire.com
Annexon stock hits 52-week low at $3.04 amid market challenges
February 12, 2025 | msn.com
See More Annexon Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Annexon? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Annexon and other key companies, straight to your email.

About Annexon

Annexon (NASDAQ:ANNX), a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis. The company is also developing ANX007, an antigen-binding fragment (Fab) that is in Phase 3 program for the treatment of patients with geographic atrophy; and ANX1502, a novel oral small molecule inhibitor, which is in Phase 1 clinical trials for autoimmune indications. In addition, it develops ANX009, a C1q-blocking Fab that is in Phase I clinical trial for treating patients with lupus nephritis. The company was incorporated in 2011 and is headquartered in Brisbane, California.

View Annexon Profile

More Earnings Resources from MarketBeat

Earnings Tools
Earnings By Country
Latest Articles